Amyotrophic Lateral Sclerosis (ALS) Pipeline

DelveInsight’s, “Amyotrophic Lateral Sclerosis Pipeline Insight, 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

Amyotrophic Lateral Sclerosis Understanding

Amyotrophic Lateral Sclerosis Overview

Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disorder that primarily affects motor neurons in the brain and spinal cord. It is characterized by the degeneration of upper motor neurons in the motor cortex and lower motor neurons in the brainstem and spinal cord, leading to progressive muscle weakness and paralysis. ALS occurs in both sporadic and familial forms, with the sporadic type accounting for approximately 90–95% of cases. The exact cause of ALS remains unknown, but it is believed to result from a combination of genetic and environmental factors. Approximately 5–10% of cases are familial and are linked to mutations in genes such as SOD1, C9orf72, TARDBP, and FUS, while the majority of cases are sporadic.

The signs and symptoms of Amyotrophic Lateral Sclerosis usually begin focally and worsen over time as the disease spreads to other muscle groups. Early manifestations include muscle weakness, stiffness, cramps, and fasciculations, often affecting the limbs or bulbar muscles. Upper motor neuron involvement results in spasticity, hyperreflexia, and exaggerated reflexes, while lower motor neuron degeneration leads to muscle atrophy, flaccid weakness, and visible fasciculations. As the disease progresses, patients may develop dysarthria, dysphagia, and difficulty chewing due to bulbar muscle involvement. In advanced stages, respiratory muscle weakness causes shortness of breath and ultimately respiratory failure. Although sensory function is generally preserved, a subset of patients may develop cognitive or behavioral impairment, including frontotemporal dementia.

The pathogenesis of Amyotrophic Lateral Sclerosis is complex and multifactorial, involving a combination of genetic susceptibility and cellular dysfunction. Mutations in genes such as SOD1, C9orf72, TARDBP, and FUS contribute to abnormal protein folding, aggregation, and impaired RNA processing. Glutamate-mediated excitotoxicity leads to excessive calcium influx and neuronal injury, while oxidative stress and mitochondrial dysfunction further accelerate motor neuron degeneration. Neuroinflammation, driven by activated microglia and astrocytes, plays a significant role in disease progression, along with defects in axonal transport and impaired cellular homeostasis.

The diagnosis of Amyotrophic Lateral Sclerosis is primarily clinical and is supported by electrophysiological and imaging studies, as there is no single definitive diagnostic test. Diagnosis requires evidence of progressive upper and lower motor neuron degeneration in multiple body regions, along with the exclusion of alternative neurological disorders. Electromyography is used to demonstrate widespread denervation and reinnervation, while nerve conduction studies help rule out peripheral neuropathies. Magnetic resonance imaging is commonly performed to exclude structural lesions, and genetic testing may be considered in familial or early-onset cases. Diagnostic frameworks such as the Revised El Escorial or Gold Coast criteria are widely used in clinical practice.

Treatment of Amyotrophic Lateral Sclerosis remains largely supportive, as there is currently no cure. Disease-modifying therapies include riluzole, which reduces glutamate-induced excitotoxicity and modestly prolongs survival, and edaravone, an antioxidant that may slow functional decline in selected patients. Symptomatic management focuses on controlling spasticity, pain, sialorrhea, and nutritional deficits, often requiring enteral feeding in advanced disease. Respiratory support with non-invasive ventilation significantly improves survival and quality of life. A multidisciplinary care approach involving neurologists, respiratory specialists, nutritionists, physical therapists, and palliative care teams is essential for optimizing patient outcomes and maintaining quality of life.

 

"Amyotrophic Lateral Sclerosis Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Amyotrophic Lateral Sclerosis pipeline landscape is provided which includes the disease overview and Amyotrophic Lateral Sclerosis treatment guidelines. The assessment part of the report embraces, in depth Amyotrophic Lateral Sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Amyotrophic Lateral Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Learn the early signs of Amyotrophic Lateral Sclerosis and act fast - early awareness improves care, planning, and quality of life overall.

Amyotrophic Lateral Sclerosis Report Highlights

• The Amyotrophic Lateral Sclerosis companies and academics are working to assess challenges and seek opportunities that could influence Amyotrophic Lateral Sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Amyotrophic Lateral Sclerosis.

Amyotrophic Lateral Sclerosis Emerging Drugs Analysis

This segment of the Amyotrophic Lateral Sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Amyotrophic Lateral Sclerosis Emerging Drugs

• Debamestrocel: Brainstorm-Cell Therapeutics

Debamestrocel (MSC-NTF, also known as NurOwn®) is an investigational, autologous cell therapy being developed for amyotrophic lateral sclerosis (ALS). It uses a patient’s own mesenchymal stromal cells (MSCs), modified to secrete high levels of neurotrophic factors (NTFs) that support neuron survival and reduce inflammation in the nervous system. The therapy is administered by intrathecal injection to deliver these protective factors directly to the spinal fluid. Debamestrocel aims to slow or stabilize ALS progression by enhancing neuronal health and modulating neuro inflammation. Currently, the drug is in Phase III stage of its development for the treatment of Amyotrophic Lateral Sclerosis.

• SLS-005: Seelos Therapeutics, Inc.

SLS-005 is an investigational therapy for Amyotrophic Lateral Sclerosis (ALS) whose active ingredient is the disaccharide trehalose. It is formulated for intravenous infusion and designed to cross the blood-brain barrier, stabilize misfolded proteins, and activate the cellular cleanup process known as autophagy. By enhancing autophagy and promoting clearance of toxic protein aggregates in motor neurons (e.g., TDP-43, SOD1), it aims to slow ALS progression. Currently, the drug is in Phase II/III stage of its development for the treatment of Amyotrophic Lateral Sclerosis.

• COYA 302: Coya Therapeutics, Inc.

COYA 302 is an investigational biologic combination therapy designed to treat Amyotrophic Lateral Sclerosis. Comprising a proprietary low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig (abatacept), it is administered subcutaneously to enhance regulatory T-cell (Treg) anti-inflammatory activity while simultaneously suppressing activated monocytes/macrophages. The dual-mechanism approach aims to rebalance immune dysregulation and reduce chronic neuro inflammation believed to drive ALS progression. As per the company pipeline, the drug is in Phase II stage of its clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS).

• HK-001: Everfront Biotech

HK-001 is an investigational small-molecule therapy developed by Everfront Biotech, Inc. for the treatment of amyotrophic lateral sclerosis. Designed as an oral soft-gel capsule formulation, HK-001 is being evaluated in early-phase clinical studies to determine its safety, tolerability, and pharmacokinetic profile in healthy volunteers and ultimately in ALS patients. Through targeted inhibition of mTOR and suppression of excessive autophagy, it aims to delay the progression of ALS in patients. Currently, HK-001 is being evaluated in the Phase I for ALS.

• QRL-201: QurAlis Corporation

QRL-201, developed by QurAlis Corporation, is therapy for amyotrophic lateral sclerosis (ALS) that specifically targets stathmin-2 (STMN2) loss, a key driver of motor neuron degeneration in ALS. The therapy is designed to restore STMN2 expression, which is disrupted due to TDP-43 protein pathology a hallmark of most ALS cases. By re-establishing normal STMN2 levels, QRL-201 aims to stabilize axons, support neuronal repair, and preserve motor function. As per the company pipeline the drug is in Phase I stage of its clinical trial for the treatment of amyotrophic lateral sclerosis.

Further product details are provided in the report……..

Amyotrophic Lateral Sclerosis Therapeutic Assessment

This segment of the report provides insights about the different Amyotrophic Lateral Sclerosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Amyotrophic Lateral Sclerosis

• There are approx. 80+ key companies which are developing the therapies for Amyotrophic Lateral Sclerosis. The companies which have their Amyotrophic Lateral Sclerosis drug candidates in the most advanced stage, i.e. phase III include, Brainstorm-Cell Therapeutics.

Amyotrophic Lateral Sclerosis Clinical Trial Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Amyotrophic Lateral Sclerosis Route of Administration

Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Amyotrophic Lateral Sclerosis Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Amyotrophic Lateral Sclerosis Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Amyotrophic Lateral Sclerosis Clinical Trial Activities

The Amyotrophic Lateral Sclerosis Pipeline report provides insights into different Amyotrophic Lateral Sclerosis clinical trials within phase II, I, preclinical and discovery stage. It also analyses Amyotrophic Lateral Sclerosis therapeutic drugs key players involved in developing key drugs.

Amyotrophic Lateral Sclerosis Pipeline Development Activities

The Amyotrophic Lateral Sclerosis clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Amyotrophic Lateral Sclerosis drugs.

Amyotrophic Lateral Sclerosis Pipeline Report Insights

• Amyotrophic Lateral Sclerosis Pipeline Analysis
• Amyotrophic Lateral Sclerosis Therapeutic Assessment
• Amyotrophic Lateral Sclerosis Unmet Needs
• Impact of Amyotrophic Lateral Sclerosis Drugs

Amyotrophic Lateral Sclerosis Pipeline Report Assessment

• Amyotrophic Lateral Sclerosis Pipeline Product Profiles
• Amyotrophic Lateral Sclerosis Therapeutic Assessment
• Amyotrophic Lateral Sclerosis Pipeline Assessment
• Amyotrophic Lateral Sclerosis Inactive drugs assessment
• Amyotrophic Lateral Sclerosis Market Unmet Needs

Support Amyotrophic Lateral Sclerosis research and patient care today - your donation funds breakthrough therapies, caregiver resources, and hope for families facing this disease.

Key Questions Answered In The Amyotrophic Lateral Sclerosis Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Amyotrophic Lateral Sclerosis drugs?
• How many Amyotrophic Lateral Sclerosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Amyotrophic Lateral Sclerosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Amyotrophic Lateral Sclerosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Amyotrophic Lateral Sclerosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Amyotrophic Lateral Sclerosis Key Players

• Brainstorm-Cell Therapeutics
• Zhimeng Biopharma
• Clene Inc.
• Abbvie
• Calico Life Sciences LLC
• Collaborative Medicinal Development, LLC
• Eledon Pharmaceuticals.
• PhenoNet, Inc.
• Kadimastem
• Corcept Therapeutics Incorporated
• Zydus Lifesciences Limited
• Novartis
• Spinogenix
• Seelos Therapeutics, Inc.
• Coya Therapeutics, Inc.
• Cellenkos
• Everfront Biotech
• Xalud Therapeutics
• QurAlis Corporation
• Alchemab
• Eli Lilly
• ProMIS Neurosciences
• Time therapeutics
• AKAVA Therapeutics
• Nevrargenics
• Biogen

Amyotrophic Lateral Sclerosis Key Products

• Debamestrocel-MSC-NTF
• CB03-154
• CNM-Au8
• Fosigotifator:
• Cu(II)ATSM
• Tegoprubart
• PHENOGENE-1A
• AstroRx cell product
• Dazucorilant
• ZYIL-1
• VHB937
• SPG302
• SLS-005
• COYA 302
• CK0803
• HK-001
• XT-150
• QRL-201
• QRL-101
• ATLX-1282
• PMN267
• TTM-003
• AKV9
• NVG645
• EPH101